This page is updated frequently with new Polypeptide-related patent applications.
|Proteomic sample preparation using paramagnetic beads|
The present invention relates to a method of reversibly binding polypeptides to a solid phase comprising a hydrophilic surface, preferably for the use in mass spectrometry based proteomics. Kits providing reagents for the method of the invention and uses of said kits..
European Molecular Biology Laboratory
|Pca3, pca3 genes, and methods of use|
The present invention relates, in general, to a prostate-specific antigen, pca3. In particular, the present invention relates to nucleic acid molecules coding for the pca3 protein; purified pca3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to pca3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding pca3 proteins; a method of detecting nucleic acids encoding pca3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal..
The Johns Hopkins University
|Isolated polynucleotides and polypeptides, and methods of using same for improving plant properties|
Provided are isolated polynucleotides which are at least 80% homologous to seq id no: 320, 1-319, 321-473, 836-1652, 1654-3221, 3225-3241, 3243-3630, 3632-4176 or 4177; and isolated polypeptides which are at least 80% homologous to seq id no: 760, 474-759, 761-770, 772-835 and 4178-4195, 4197-4213, 4215-4216, 4218-5334, 5336-5522, 5524-5754, 5756-6215, 6217, 6220-6223, 6230, 6232, 6235-6607, 6609-6614, 6620-7129 or 7130, nucleic acid constructs comprising the isolated polynucleotides, transgenic plants expressing same and methods of using same for increasing abiotic stress tolerance, yield, biomass, growth rate, vigor, oil content, fiber yield, fiber quality, and/or nitrogen use efficiency of a plant.. .
|Synthetic chloroplast transit peptides|
This disclosure concerns compositions and methods for targeting peptides, polypeptides, and proteins to plastids of plastid-containing cells. In some embodiments, the disclosure concerns chloroplast transit peptides that may direct a polypeptide to a plastid, and nucleic acid molecules encoding the same.
Dow Agrosciences Llc
|Polypeptides having xanthan degrading activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having xanthan degrading activity, catalytic domains and polynucleotides encoding the polypeptides and catalytic domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides and catalytic domains..
|Engineered biocatalysts useful for carbapenem synthesis|
The present disclosure provides engineered pnb esterase polypeptides useful for the synthesis of the carbapenem antibiotic, imipenem. The disclosure also provides polynucleotides encoding the engineered pnb esterases, host cells capable of expressing the engineered pnb esterases, and methods of using the engineered pnb esterases in the production of imipenem..
|Polypeptides having organophosphorous hydrolase activity|
The present invention relates to isolated polypeptides having organophosphorous hydrolase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
The present disclosure provides engineered transaminase enzymes having improved properties as compared to a naturally occurring wild-type transaminase enzyme. Also provided are polynucleotides encoding the engineered transaminase enzymes, host cells capable of expressing the engineered transaminase enzymes, and methods of using the engineered transaminase enzymes to synthesize a variety of chiral compounds..
|Il-17a/f heterologous polypeptides and therapeutic uses thereof|
The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17f designated herein as interleukin 17a/f (il-17a/f). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
|Anti-activin a antibodies and uses thereof|
The disclosure provides compositions and methods relating to or derived from anti-activin a binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin a antibodies that bind human activin a, activin a-binding fragments and derivatives of such antibodies, and activin a-binding polypeptides comprising such fragments.
Mrka polypeptides, antibodies, and uses thereof
The present disclosure provides mrka binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to mrka and induce opsonophagocytic killing of klebsiella (e.g., klebsiella pneumoniae). The present disclosure also provides methods of reducing klebsiella (e.g., klebsiella pneumoniae) or treating or preventing klebsiella (e.g., klebsiella pneumoniae) infection in a subject comprising administering mrka binding proteins, e.g., antibodies or antigen-binding fragments thereof, mrka polypeptides, immunogenic fragments thereof, or polynucleotides encoding mrka or immunogenic fragments thereof to the subject..
Factor viii chimeric proteins and uses thereof
The present invention provides a chimeric protein comprising a first polypeptide which comprises a fviii protein and a first ig constant region or a portion thereof and a second polypeptide which comprises a vwf protein comprising the d′ domain and d3 domain of vwf, a xten sequence having less than 288 amino acids in length, and a second ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins..
Biogen Ma Inc.
Osteoprotegerin derived rankl inhibitor
A pharmaceutical composition is described that can be used for treating or prevention of diseases association with bone resorption, particularly of a metastatic carcinoma. In certain aspects, the composition is based on a polypeptide which includes the leading 215 amino acids of the human osteoprotegerin followed by the fc portion of the human igg1 protein.
R-pharm Overseas, Inc.
Gitrl fusion proteins and uses thereof
The disclosure provides gitrl fusion polypeptide subunits comprising an igg fc domain, a trimerization domain, and the receptor binding domain of gitr ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g., treatment of cancer..
Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory
The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/g-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of alzheimer's disease.. .
The Regents Of The University Of California
Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells
Methods for expressing a polypeptide of interest in an astroglial cell. The methods permit the localization and transport of nucleic acids in microglial exosomes, the reprogramming of astroglial cells to neuronal cells, and the treatment of ischemic stroke or traumatic brain injury patients..
Nomadogen Biotechnologies Inc.
Enhanced influenza hemagglutinin binders
Designed polypeptides having the amino acid sequence of seq id nq: 1 are described that bind with high affinity and selectivity to the influenza hemagglutinin protein, and which can be used for treating and/or limiting an influenza infection, as well as diagnosing an influenza infection and identifying candidate compounds for treating an influenza infection.. .
University Of Washington
Inflammation-enabling polypeptides and uses thereof
This present technology relates to the use of inflammation-enabling polypeptides (or their coding sequences) to screen for agents useful for the prevention, treatment and/or alleviations of symptoms associated with an inflammatory disorder, to identify individuals susceptible of developing an exacerbated inflammatory response as well as to determine if a therapeutic regimen is capable of preventing, treating or alleviating the symptoms associated to an inflammatory disorder in an individual. The present technology also provides methods for preventing, treating and/or alleviating the symptoms associated to an inflammatory condition based on the inhibition of expression or activity of the inflammation-enabling targets..
The Royal Institution For The Advancement Of Learning/mcgill University
Composition for treating hbv infection
The present invention provides a composition comprising hepatitis b virus (hbv) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such hbv component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors.
Influenza hemagglutinin proteins and methods of use thereof
In some embodiments the present invention provides influenza hemagglutinin (“ha”) polypeptides, proteins, and protein complexes that comprise a stalk domain that is engineered to facilitate maintenance of its native trimeric conformation, even if the head domain of the ha protein is removed or disrupted. In some embodiments, the present invention provides compositions comprising such polypeptides, proteins, and protein complexes, and methods of use of such proteins and compositions, for example as vaccine immunogens..
Avatar Medical, Llc
Ehrlichial invasin for immuniztion, diagnosis, and cell delivery
Disclosed are vaccines containing one or more immunogenic polypeptides derived from an etpe protein from an ehrlichia sp. Or nucleic acid encoding these polypeptides.
Ohio State Innovation Foundation
Mesothelin vaccines and model systems
Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic t cell response.
The Johns Hopkins University
Malaria vaccines based on pre-erythrocytic antigens from p. falciparum
The present invention relates to polypeptides or fragments thereof for use as malaria vaccines. It also relates to nucleic acid molecules coding for the polypeptides of the invention.
Neurotoxins exhibiting shortened biological activity
The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a neurotoxin polypeptide exhibiting a reduced duration of biological effect in a subject, wherein the polypeptide comprises at feast one degradation signal in the light chain as well as vectors and host calls comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides.
Merz Pharma Gmbh & Co. Kgaa
Polypeptide inhibitors of hsp27 kinase and uses therfor
The present invention provides polypeptide inhibitors of hsp27 kinase, compositions thereof, and methods for using such polypeptides and compositions for various therapeutic uses.. .
Purdue Research Foundation
Mutant ros expression in human cancer
The invention provides the identification of the presence of mutant ros protein in human cancer. In some embodiments, the mutant ros are fig-ros fusion proteins comprising part of the fig protein fused to the kinase domain of the ros kinase.
Cell Signaling Technology, Inc.
Method for production of polypeptides
The current invention reports a promoter that has the nucleic acid sequence of seq id no: 02 or seq id no: 03 which is a human cmv major immediate-early (hcmv-mie) promoter/enhancer with c to g point mutation at position −41 and/or −179 relative to the transcription start site. This new promoter is especially useful for the production of polypeptides at large scale as it shows reduced promoter silencing and improved polypeptide production..
Hoffmann-la Roche Inc.
Parainfluenza virus 5 based vaccines
The present invention provides safe, stable, efficacious, and cost-effective vaccines based on viral expression vectors that include a parainfluenza virus 5 (piv5) genome including a heterologous nucleotide sequence expressing a heterologous polypeptide.. .
University Of Georgia Research Foundation, Inc.
Expression vector system comprising two selection markers
Wherein the activity of the selectable marker (sm i) or (sm ii) is at least partially influenced by the activity of the other selectable marker and wherein the selectable markers (sm i) and (sm ii) are involved in the folate metabolism. Also provided are suitable host cells, selection methods and methods for producing polypeptides with high yield..
Transcription factor sequences for conferring advantageous properties to plants
The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference or control plant, including increased plant size, seed size, increased leaf size, lignification, water deprivation tolerance, cold tolerance, or altered flowering time. Sequence information related to these polynucleotides and polypeptides can also be used in bioinformatic search methods and is also disclosed..
Mendel Biotechnology, Inc.
Plants having one or more enhanced yield-related traits and a making the same
Provided is a method for enhancing one or more yield-related traits in a plant by modulating expression in the plant of a nucleic acid encoding an anac055 (arabidopsis no apical meristem, arabidopsis transcription factor, cup-shaped cotyledon) polypeptide. Also provided are plants having modulated expression of a nucleic acid encoding an anac055 polypeptide, which plants have one or more enhanced yield-related traits compared with control plants.
Basf Plant Science Company Gmbh
Microorganisms engineered for increased productivity
The application provides recombinant microorganisms with increased productivity with respect to control or wildtype microorganisms. The recombinant microorganisms can include a non-native gene encoding a skp1 polypeptide or a chord-derived polypeptide.
Synthetic Genomics, Inc.
Haploid induction compositions and methods for use therefor
Also provided are expression cassettes; vectors; transgenic plant cells; plants, plant parts, and seeds; isolated polypeptides; amplicons and informative fragments of the presently disclosed nucleic acids; compositions that include amplification primer pairs; methods for producing plants that exhibit hi; methods for identifying the presence or absence of an allele associated with hi in a plant; methods for introgressing haploid—inducing nucleotide sequences into plants; and methods for selecting parental plants predicted to produce progeny generations with plants that exhibit haploid induction trait.. .
The invention relates to a method for altering the conformational diversity of a first repertoire of polypeptide ligands, comprising a plurality of polypeptides comprising at least two reactive groups separated by a loop sequence covalently linked to a molecular scaffold which forms covalent bonds with said reactive groups, to produce a second repertoire of polypeptide ligands, comprising assembling said second repertoire from the polypeptides and structural scaffold of said first repertoire, incorporating one of the following alterations: (a) altering at least one reactive group; or (b) altering the nature of the molecular scaffold; or (c) altering the bond between at least one reactive group and the molecular scaffold; or (d) any combination of (a), (b) or (c).. .
Bicycle Therapeutics Limited
Biocatalysts and methods for the synthesis of armodafinil
The present invention relates to non-naturally occurring polypeptides useful for preparing armodafinil, polynucleotides encoding the polypeptides, and methods of using the polypeptides. The non-naturally occurring polypeptides of the present invention are effective in carrying out biocatalytic conversion of the (i) 2-(benzhydrylsulfinyl)acetamide to (−)-2-[(r)-(diphenylmethyl)sulfinyl]acetamide (armodafinil), or (ii) benzhydryl-thioacetic acid to (r)-2-(benzhydrylsulfinyl)acetic acid, which is a pivotal intermediate in the synthesis of armodafinil, in enantiomeric excess..
Ketoreductase polypeptides for the reduction of acetophenones
The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds..
Protein-containing adhesives, and manufacture and use thereof
The invention provides protein adhesives and methods of making and using such adhesives. The protein adhesives contain ground plant meal or an isolated polypeptide composition obtained from plant biomass..
Nucleotide and amino acid sequences relating to respiratory diseases and obesity
This invention relates to genes identified from human chromosome 12q23-qter, which are associated with various diseases, including asthma. The invention also relates to the nucleotide sequences of these genes, isolated nucleic acids comprising these nucleotide sequences, and isolated polypeptides or peptides encoded thereby.
Oscient Pharmaceuticals Corporation
Therapeutic il-13 polypeptides
Variant il-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for il-13rα2, relative to the native human il-13 protein; (b) altered affinity for il-13rα1 relative to the native human il-13 protein; (c) a disruption in the binding site for il-4rα relative to the native human il-13 protein.. .
The Board Of Trustees Of The Leland Stanford Junior University
Opsin polypeptides and methods of use thereof
The present disclosure provides opsins, including variant opsins with increased activity and/or increased trafficking to the plasma membrane. The opsins are useful in therapeutic and screening applications, which are also provided..
The Board Of Trustees Of The Leland Stanford Junior University
Isolated polypeptides and polynucleotides encoding same for generating plants with increased cuticlar water permeability
An isolated polynucleotide is provided. The isolated polynucleotides comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 88% homologous to seq id no: 22, the polypeptide being capable of increasing a cuticular water permeability of a plant expressing same.
The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organizat
The present invention provides inventive stitched polypeptides, pharmaceutical compositions thereof, and methods of making and using inventive stitched polypeptides.. .
President And Fellows Of Harvard College
Automatic gas valve container holder for chemical synthesis
The invention relates to a container holder 10, comprising a main body 12 which in turn comprises a gas inlet 16; a solution liquid outlet 18; a gas control valve 20 through which a gas enters the container 100 from the gas inlet; and a sealing means 22 for the container, which sealing means includes a passageway 24 for the input of gas and output of a solution in the container via an egress tube 19; wherein when the container is connected to the container holder through the sealing means, the gas control valve opens automatically, and when the container is disconnected the gas control valve is closed automatically. The invention further relates to a container panel 50 which includes two or more container holders.
Ge Healthcare Bio-sciences Ab
Compounds and methods for the targeted degradation of bromodomain-containing proteins
The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a vhl ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein.
The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irrespective of whether the antigen is derived from a membrane or non-membrane protein.
The Johns Hopkins University
Adenoviral vector vaccine
Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of cd40 ligand, which is missing all or substantially all of the transmembrane domain rendering cd40l secretable.
Novel compositions and methods
The present invention is directed to a polypeptide which comprises: (i) an rv2386c protein sequence; (ii) a variant of an rv2386c protein sequence; of (iii) an immunogenic fragment of an rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis..
Glaxosmithkline Biologicals S.a.
Compositions containing alpha-1-antitrypsin and methods for use
Methods and compositions for treating patients (e.g., patients who are insulin resistant, patients who have diabetes, or are at risk for developing diabetes) are disclosed herein. The methods can include administration of an al antitrypsin (aat) polypeptide or an agent, such as a nucleic acid molecule or organic compound, that promotes the expression or activity of α1-antitrypsin..
The General Hospital Corporation
Composition exhibiting a von willebrand factor (vwf) protease activity comprising a polypeptide chain with the amino acid sequence aaggilhlellv
The invention relates to vwf cleaving entities having a molecular weight of 180 kd, 170 kd, 160 kd, 120 kd or 110 kd and an n-terminal amino acid sequence of aaggilhlellv, vwf cleaving complexes and methods for their production.. .
Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
The invention relates to the identification of new therapeutic methods for the fgf21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. Insulin receptor mutation disorders (insr disorders) and/or autoimmune insulin receptor disorders (type b insulin resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (nafld), and other metabolic disorders, and various lipodystrophies such as hiv-haart induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients..
Methods for treating immune mediated neurological diseases
Polypeptides and other compounds that can bind specifically to the ch2-ch3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit fc-mediated immune complex formation, immune complexed igg to igg fγr binding, and immune complexed igg mc1q (membrane c1q) or soluble c1q binding. Such compounds may have therapeutic use in treating amyotrophic lateral sclerosis (als), parkinson's disease (pd), and alzheimer's disease (ad)..
Trinity Therapeutics, Inc.